Cidara, Janssen To Tackle Flu With Antiviral Conjugates

Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.

Influenza A H7N9
Cidara and Janssen hope AVCs offer a path to universal flu protection

Clinical-stage Cidara Therapeutics, Inc. says its antiviral conjugate (AVC) platform can offer better protection against seasonal and pandemic influenza than vaccines and now has a co-development and licensing deal with Janssen Pharmaceuticals Inc. to advance its efforts. The San Diego biotech is developing AVCs for flu and other infectious diseases to broaden its business prospects beyond its Phase III antifungal rezafungin.

[Sidebar#SC100594]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.